Royal Bank of Canada’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $0 | Buy |
75
+10
| +15% | +$8 | ﹤0.01% | 7535 |
|
|
2025
Q4 | $0 | Sell |
65
-1,798
| -97% | -$1.62K | ﹤0.01% | 7502 |
|
|
2025
Q3 | $2K | Sell |
1,863
-5,281
| -74% | -$6.21K | ﹤0.01% | 6899 |
|
|
2025
Q2 | $9K | Buy |
7,144
+6,856
| +2,381% | +$9.31K | ﹤0.01% | 6512 |
|
|
2025
Q1 | $0 | Sell |
288
-1,202
| -81% | -$1.71K | ﹤0.01% | 7139 |
|
|
2024
Q4 | $2K | Sell |
1,490
-1,102
| -43% | -$2.92K | ﹤0.01% | 6725 |
|
|
2024
Q3 | $10K | Sell |
2,592
-9,016
| -78% | -$30.1K | ﹤0.01% | 6338 |
|
|
2024
Q2 | $34K | Buy |
11,608
+8,627
| +289% | +$27.6K | ﹤0.01% | 5833 |
|
|
2024
Q1 | $12K | Sell |
2,981
-8,154
| -73% | -$42K | ﹤0.01% | 6135 |
|
|
2023
Q4 | $56K | Buy |
11,135
+5,300
| +91% | +$26.3K | ﹤0.01% | 5930 |
|
|
2023
Q3 | $30K | Buy |
5,835
+3,851
| +194% | +$21.1K | ﹤0.01% | 6028 |
|
|
2023
Q2 | $10K | Buy |
1,984
+1,734
| +694% | +$11.4K | ﹤0.01% | 6480 |
|
|
2023
Q1 | $2K | Hold |
250
| – | – | ﹤0.01% | 6786 |
|
|
2022
Q4 | $3K | Sell |
250
-2
| -0.8% | -$14 | ﹤0.01% | 6868 |
|
|
2022
Q3 | $1K | Buy |
252
+2
| +0.8% | +$8 | ﹤0.01% | 7238 |
|
|
2022
Q2 | $1K | Sell |
250
-1,172
| -82% | -$5.57K | ﹤0.01% | 7174 |
|
|
2022
Q1 | $9K | Buy |
1,422
+917
| +182% | +$5.7K | ﹤0.01% | 7006 |
|
|
2021
Q4 | $4K | Buy |
+505
| New | +$5.43K | ﹤0.01% | 7282 |
|
|
2021
Q2 | – | Sell |
-4,000
| Closed | -$18K | – | 7627 |
|
|
2021
Q1 | $18K | Buy |
+4,000
| New | +$16.1K | ﹤0.01% | 6485 |
|
|
2019
Q3 | – | Sell |
-360
| Closed | -$2K | – | 7007 |
|
|
2019
Q2 | $2K | Buy |
+360
| New | +$2.35K | ﹤0.01% | 6590 |
|
|
2019
Q1 | – | Sell |
-1
| Closed | – | – | 7022 |
|
|
2018
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 7021 |
|
|
2018
Q3 | $0 | Sell |
1
-11
| -92% | -$198 | ﹤0.01% | 6891 |
|
|
2018
Q2 | $0 | Sell |
12
-118
| -91% | -$2.46K | ﹤0.01% | 6700 |
|
|
2018
Q1 | $3K | Sell |
130
-8
| -6% | -$2.15K | ﹤0.01% | 6053 |
|
|
2017
Q4 | $25K | Sell |
138
-82
| -37% | -$16.5K | ﹤0.01% | 5511 |
|
|
2017
Q3 | $47K | Buy |
220
+94
| +75% | +$19.4K | ﹤0.01% | 5450 |
|
|
2017
Q2 | $25K | Sell |
126
-26
| -17% | -$5.12K | ﹤0.01% | 5457 |
|
|
2017
Q1 | $28K | Sell |
152
-18
| -11% | -$3.56K | ﹤0.01% | 5457 |
|
|
2016
Q4 | $43K | Buy |
170
+50
| +42% | +$11.4K | ﹤0.01% | 5346 |
|
|
2016
Q3 | $25K | Hold |
120
| – | – | ﹤0.01% | 5464 |
|
|
2016
Q2 | $24K | Hold |
120
| – | – | ﹤0.01% | 5433 |
|
|
2016
Q1 | $22K | Buy |
120
+70
| +140% | +$12.5K | ﹤0.01% | 5448 |
|
|
2015
Q4 | $13K | Buy |
+50
| New | +$16.1K | ﹤0.01% | 5884 |
|
Other funds holding PDSB
VCM
VFT
IWA
AC
Royal Bank of Canada's PDSB Position: Q1 2026 in Review
Royal Bank of Canada increased its PDS Biotechnology (PDSB) stake by 15% in Q1 2026, buying an estimated $8 and bringing the position to 75 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7535.
Royal Bank of Canada first reported a position in PDSB in Q4 2015 and has held it in 33 quarters since. The position peaked at $56K in Q4 2023. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.
- Royal Bank of Canada held 75 shares of PDS Biotechnology worth $0 as of Q1 2026.
- Royal Bank of Canada bought 10 PDS Biotechnology shares in Q1 2026, an estimated $8.
- PDS Biotechnology made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7535 holding.
- Royal Bank of Canada first reported a position in PDS Biotechnology in Q4 2015 and has held it in 33 quarters since.
- Royal Bank of Canada's PDS Biotechnology position peaked at $56K in Q4 2023.
- 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.